NHS saves £1.2 billion on medicines over three years

1 July 2022 - The NHS has saved taxpayers £1.2 billion in just three years, while securing cutting-edge treatments for ...

Read more →

People dying of COVID while life-saving drugs go unused, doctors say

21 May 2022 - Top doctors have warned that vulnerable patients who test positive to COVID-19 are missing out on ...

Read more →

Prioritising reference products over biosimilars led to millions of missed savings for Part D

20 April 2022 - Medicare Part D plans missed out on between $84 million and $143 million in savings by ...

Read more →

Some hoped FDA approval of Pfizer's COVID vaccine would convince unvaccinated Americans. It didn't, study finds.

6 April 2022 - After the Food and Drug Administration approved Pfizer-BioNTech’s COVID-19 vaccine in August, public health experts were ...

Read more →

DUSC outcome statement

25 March 2022 - The outcome statement from the February 2022 DUSC meeting is now available. ...

Read more →

DUSC utilisation analysis public release documents

25 March 2022 - The utilisation analysis public release documents from the October 2021 DUSC meeting are now available. ...

Read more →

Medscape awarded contract from FDA to develop educational programming focused on biosimilars

14 February 2022 - Medscape Education has been awarded a contract from the U.S. FDA for the development of an ...

Read more →

Are we measuring what matters most on uptake to medicines in England?

16 November 2021 - VPAS is a voluntary agreement between the UK government and the Association of the British Pharmaceutical ...

Read more →

Drug Utilisation Sub-Committee outcome statement

5 November 2021 - The Outcome Statement from the October 2021 Drug Utilisation SubCommittee meeting is now available. ...

Read more →

Patient and payer incentives to use patented brand name drugs vs authorised generic drugs in Medicare Part D

18 October 2021 - This cross-sectional study of Medicare formulary and pricing data for quarter 3 of 2020 found that most ...

Read more →

Real world use of and spending on new oral targeted cancer drugs in the US (2011-2018)

18 October 2021 - In this cross-sectional study among 37 348 patients who received 1 or more of 44 new oral targeted ...

Read more →

Sales of Biogen’s costly new Alzheimer’s drug fall far short of expectations

20 October 2021 - The drug maker Biogen reported on Wednesday that Aduhelm, its new Alzheimer’s drug, brought in $300,000 ...

Read more →

Docs ‘use rubber stamp for drugs’

9 October 2021 - Pharmacists have raised the alarm over the influence of a US pharmaceutical corporation on Australian doctors ...

Read more →

Barriers to US biosimilar market growth: lessons from biosimilar patent litigation

6 August 2021 - High biologic drug prices have placed substantial strain on the US health care system.  ...

Read more →

Competition from biosimilars drives price reductions for biologics in the French single payer health system

6 August 2021 - France has a single payer health insurance system that has the authority to impose pharmaceutical price reductions ...

Read more →